1. Patients and Families
  2. Clinical Trial Database
  3. Canadian clinical trial registry

Canadian clinical trial registry

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

1 results found

Title
Status

 

MK-4280-003 - A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Open

More information

MK-4280-003 - A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Go to Health Care Provider version

DiagnosisHodgkin Disease Lymphoma, Non-Hodgkin Lymphoma, B-CellStudy StatusOpen
PhaseI/II
Age18 Years and olderRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationBiological: Pembrolizumab (KEYTRUDA®) Administered as an IV infusion every 3 weeks (Q3W) Biological: Favezelimab (MK-4280) Administered as an IV infusion Q3W
Last Posted Update2024-08-21
ClinicalTrials.gov #NCT03598608
International Sponsor
Merck Sharp & Dohme LLC
Principal Investigators for Canadian Sites
CancerCare Manitoba - Dr. Leonard Minuk
Centres
Medical contact

Sarcoma - Dr. Sapna Oberoi

soberoi@cancercare.mb.ca

Social worker/patient navigator contact
N/A
Clinical research contact

Rebekah Hiebert

rhiebert5@cancercare.mb.ca

Kathryn Dyck

kdyck5@cancercare.mb.ca

 

 

Study Description

This study will evaluate the combination of two drugs called favezelimab and pembrolizumab to see how effective and safe it is for treating patients with a cancer called lymphoma. There are various different kinds of lymphoma, this study is for patients with classical Hodgkin, indolent non-Hodgkin or diffuse large B-cell lymphoma. 

Inclusion Criteria
  • Participants must be 18 years of age or older 
  • Participants must have a diagnosis of:
    • classical Hodgkin lymphoma (cHL)
    • diffuse large B-cell lymphoma (DLBCL)
    • indolent non-Hodgkin lymphoma (iNHL)
  • Must have a tumour that can be measured on CT or MRI 
  • Participant should be well enough to carry out light daily tasks, e.g., light house work, office work, normal activities

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.